Figure 4From: Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer Kaplan-Meier survival estimates of BCSS (A, C) and DFS (B, D) in IBC patients treated with tamoxifen (A, B) but not endocrine therapy (C, D) with low (dotted line) and high (continuous line) stromal VEGF-A. The numbers of patients at risk of death from IBC are shown at 12, 24, 36 and 48 months below the x axis.Back to article page